

South Carolina  
**Department of Health and Human Services**  
Post Office Box 8206  
Columbia, South Carolina 29202-8206

**Pharmacy and Therapeutics (P&T) Committee Meeting**  
**November 1, 2023**  
MINUTES

**1. Call to Order**

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, November 1, 2023.

**2. Welcome**

Edward Behling, MD, called the meeting to order and welcomed members, guests, and staff members.

Dr. Behling opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

**3. Committee Members Present:**

Edward Behling, MD  
Kimberly Rudd, MD  
Cheryl Hartvigsen, RPh

Jony Bolinger, MD  
Patricia Witherspoon, MD

Philip Mubarak, MD  
Thomas Phillips, RPh

**SC DHHS Staff:**

Cheryl Anderson BS, RPh  
Kevin Wessinger, MD  
Kim Bristow, RPh  
Brandie Crider  
Ashley Sirianni, DNP, FNP-BC  
Sarah Hearn-Bailey, JD

**Magellan Medicaid Admin:**

Lisa Correll, PharmD  
Lori Ash

**4. Discussion Topics**

**A. Committee Meeting Minutes, Wednesday, August 2, 2023**

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

**B. Public Comment**

Company	Speaker	Drug/Class

- No speakers

**C. Drug Classes for Review**

*Classes for Re-review*

Attention Deficit Hyperactivity Disorder Agents: Extended Release  
 Anticholinergics, Inhaled  
 Beta Adrenergic Short Acting Inhalers

The chart below represents the recommendations from the P & T Committee:

<b>ATTENTION DEFICIT HYPERACTIVITY DISORDER: EXTENDED RELEASE/STIMULANTS</b>	
Preferred	Non-Preferred
Adderall XR®	Adenzys XR OCT®
Concerta®	amphetamine ER
Daytrana‡	dexmethylphenidate ER
Dyanavel® suspension	dextroamphetamine ER
dextroamphetamine tabs/caps	dextroamphetamine transdermal
Dexmethylphenidate XR	lisdexamfetamine dimesylate
methylphenidate ER	methylphenidate ER
methylphenidate IR/LA/SR	methylphenidate ER (Aptensio XR)
Quillivant XR	methylphenidate ER (Contempla XR-ODT)
Quillichew	methylphenidate ER (Jornay PM)
Vyvanse tabs/caps	methylphenidate ER (Quillichew)
	methylphenidate ER (Quillivant)
	methylphenidate ER (Ritalin LA)
	methylphenidate ER OROS
	methylphenidate transdermal
	mixed amphetamine salts ER (Adderall XR)
	mixed amphetamine salts ER (Mydayis)
	serdexmethylphenidate/dexmethylphenidate
<b>ANTICHOLINERGICS, INHALED</b>	
Preferred	Non-Preferred
Anoro Ellipta® DPI‡	Bevespi Aerosphere®+
Atrovent HFA®	Breztri Aerosphere®
Combivent Respimat® MDI	Duaklir Pressair® DPI
Incruse Ellipta® DPI‡	Spiriva Respimat®
Spiriva® Handihaler DPI	Trelegy Ellipta

<b>ANTICHOLINERGICS, INHALED (continued)</b>	
Preferred	Non-Preferred
Stiolto Respimat®	Tudorza Pressair® DPI
	Yupelri®
<b>BETA ADRENERGIC SHORT ACTING INHALERS</b>	
Preferred	Non-Preferred
ProAir HFA®	albuterol HFA
Proventil HFA®	levalbuterol
Ventolin HFA®‡	ProAir Digihaler®
Xopenex® HFA‡	ProAir RespiClick®

- ‡ Added as “Preferred”  
 + Moved to “Non-Preferred”

**5. Old Business**

None

**6. New Business**

Cheryl Anderson RPh, SC Pharmacy Director, updated the Committee on the “Pharmacy Access Act” which became effective October 1, 2023. This act allows pharmacists to provide hormonal therapies to SC Medicaid recipients. Pharmacist enrollment began September 18, 2023. Dr. Wessinger, Chief Medical Officer, shared the agency’s plan to transition to Single PDL effective July 1, 2024. Single PDL will include a unified PDL and PA criteria for FFS and all MCOs. SC DHHS is covering all vaccines on the ACIP recommended schedule, including but not limited to vaccines for shingles, travel and RSV, for adults with no cost share (\$0 copay). All vaccines are covered under the medical benefit and some are covered via the pharmacy benefit.

Lisa Correll presented new drugs to market and shared the cadence of PDL updates which occur every January and July. Pharma meetings are offered for 1 entity per year and remain virtual.

**7. Resolved Items**

*Classes for Re-review*

Attention Deficit Hyperactivity Disorder Agents: Extended Release  
 Anticholinergics, Inhaled  
 Beta Adrenergic Short Acting Inhalers

**8. Closing Comments**

The next meeting will be held Wednesday, February 7, 2024.

**9. Adjournment**

The meeting adjourned at 4:57 p.m.